Immunitybio Inc (IBRX) stock news · rev $113.3M
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
This IBRX news page leads with what Immunitybio Inc filed — not a scraped headline mill.
No cached 8-K sentence for IBRX yet. We will not pad this page with generic market recap.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the IBRX stock page; for the tape open the quote page.
IBRX stock news FAQ
What are IBRX's latest revenue and net income?
Latest cached Immunitybio Inc (IBRX) revenue for Dec 31, 2025 was $113.3M. Net income was -$351.4M. Statements: https://lician.com/financials/ibrx
How did IBRX revenue change from the prior cached period?
Cached Immunitybio Inc (IBRX) revenue was up 668.3% from $14.7M (Dec 31, 2024) to $113.3M (Dec 31, 2025). Statements: https://lician.com/financials/ibrx
What is IBRX's market cap?
Immunitybio Inc (IBRX) market cap is $7.88B on the latest cached fundamentals snapshot.
What kind of company is IBRX?
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Where is IBRX stock news listed?
Cached stock news for Immunitybio Inc (IBRX) is listed at https://lician.com/news/ibrx. Filings: https://lician.com/sec/ibrx
Not investment advice.